Purpose-built for physicians
CHICAGO — Most adults receiving a once-weekly hypoparathyroidism therapy were able to maintain normal calcium levels at 12 weeks without active vitamin D and oral calcium supplementation, according to data from a phase 2 trial.
Mishaela R. Rubin, MD, assistant professor of clinical medicine at Columbia University Irving Medical Center in New York, said conventional management of hypoparathyroidism with vitamin D and calcium supplementation does not address all complications of the disease. As Healio previously reported, the FDA approved palopegteriparatide (Yorvipath, Ascendis Pharma) for the treatment of hypoparathyroidism in August 2024.
However, Rubin noted that palopegteriparatide is a once-daily therapy. During a presentation at ENDO 2026, Rubin presented data from the Avail trial of canvuparatide (MBX Biosciences), a once-weekly therapy that is a long-acting prodrug of a parathyroid hormone analog.
“The goal of treatment with canvuparatide is to extend [half-life] further and to allow for once-weekly treatment of [hypoparathyroidism], thus hopefully reducing the treatment burden for patients,” Rubin said during a presentation.
